Capanni Cristina, Mattioli Elisabetta, Columbaro Marta, Lucarelli Enrico, Parnaik Veena K, Novelli Giuseppe, Wehnert Manfred, Cenni Vittoria, Maraldi Nadir M, Squarzoni Stefano, Lattanzi Giovanna
ITOI, CNR, Unit of Bologna, c/o IOR, Bologna, Italy.
Hum Mol Genet. 2005 Jun 1;14(11):1489-502. doi: 10.1093/hmg/ddi158. Epub 2005 Apr 20.
Lipodystrophies are a heterogeneous group of human disorders characterized by the anomalous distribution of body fat associated with insulin resistance and altered lipid metabolism. The pathogenetic mechanism of inherited lipodystrophies is not yet clear; at the molecular level they have been linked to mutations of lamin A/C, peroxisome proliferator-activated receptor (PPARgamma) and other seemingly unrelated proteins. In this study, we examined lamin A/C processing in three laminopathies characterized by lipodystrophic phenotypes: Dunnigan type familial partial lipodystrophy, mandibuloacral dysplasia and atypical Werner's syndrome. We found that the lamin A precursor was specifically accumulated in lipodystrophy cells. Pre-lamin A was located at the nuclear envelope and co-localized with the adipocyte transcription factor sterol regulatory element binding protein 1 (SREBP1). Using co-immunoprecipitation experiments, we obtained the first demonstration of an in vivo interaction between SREBP1 and pre-lamin A. Binding of SREBP1 to the lamin A precursor was detected in patient fibroblasts as well as in control fibroblasts forced to accumulate pre-lamin A by farnesylation inhibitors. In contrast, SREBP1 did not interact in vivo with mature lamin A or C in cultured fibroblasts. To gain insights into the effect of pre-lamin A accumulation in adipose tissue, we inhibited lamin A precursor processing in 3T3-L1 pre-adipocytes. Our results show that pre-lamin A sequesters SREBP1 at the nuclear rim, thus decreasing the pool of active SREBP1 that normally activates PPARgamma and causing impairment of pre-adipocyte differentiation. This defect can be rescued by treatment with troglitazone, a known PPARgamma ligand activating the adipogenic program.
脂肪营养不良是一组异质性人类疾病,其特征是身体脂肪分布异常,伴有胰岛素抵抗和脂质代谢改变。遗传性脂肪营养不良的发病机制尚不清楚;在分子水平上,它们与核纤层蛋白A/C、过氧化物酶体增殖物激活受体(PPARγ)以及其他看似无关的蛋白质的突变有关。在本研究中,我们研究了三种以脂肪营养不良表型为特征的核纤层蛋白病中的核纤层蛋白A/C加工过程:邓尼根型家族性部分脂肪营养不良、下颌骨肢端发育不良和非典型沃纳综合征。我们发现核纤层蛋白A前体在脂肪营养不良细胞中特异性积累。前体核纤层蛋白A位于核膜,与脂肪细胞转录因子固醇调节元件结合蛋白1(SREBP1)共定位。通过免疫共沉淀实验,我们首次证明了SREBP1与前体核纤层蛋白A在体内存在相互作用。在患者成纤维细胞以及通过法尼基化抑制剂被迫积累前体核纤层蛋白A的对照成纤维细胞中,检测到SREBP1与核纤层蛋白A前体的结合。相比之下,在培养的成纤维细胞中,SREBP1在体内不与成熟的核纤层蛋白A或C相互作用。为了深入了解前体核纤层蛋白A在脂肪组织中积累的影响,我们在3T3-L1前脂肪细胞中抑制核纤层蛋白A前体的加工。我们的结果表明,前体核纤层蛋白A将SREBP1隔离在核边缘,从而减少了通常激活PPARγ的活性SREBP1的数量,并导致前脂肪细胞分化受损。这种缺陷可以通过使用曲格列酮治疗来挽救,曲格列酮是一种已知的激活脂肪生成程序的PPARγ配体。